EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSPNAG00000015778
Gene Symbol: PDE9A
3 Cross references
184 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPNAG00000005905
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPNAG00000010211
Gene Symbol: PIK3R3
3 Cross references
159 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPNAG00000011138
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSPNAG00000010137
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSPNAG00000001951
Gene Symbol: PLG
3 Cross references
256 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSPNAG00000007521
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSPNAG00000023423
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSPNAG00000006989
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSPNAG00000011017
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSPNAG00000008870
Gene Symbol: LOC108440964
3 Cross references
203 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSPNAG00000017922
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).